# Parasite Diagnostics Map: O&P, Antigen, PCR, and Serology

> Match method to syndrome: microscopy O&P, stool antigen, multiplex PCR, and serology each answer different questions—with different false-negative windows.

*Published 2026-07-10 · By Julian Hart*

In short

Map method → pathogen: **O&P / antigen / PCR / serology / tape test** are not interchangeable. Steward tests with pretest probability; confirm before drugs.

Diagnostic chaos feeds the cleanse industry. This map is how clinicians match tools to bugs without treating every bloating story as occult Ascaris.

*This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, equipment, or management of a diagnosed condition. Seek urgent care for emergencies.*

## What does stool microscopy still do well?

Morphologic ID of many helminth eggs and some protozoa when load is adequate.

Requires expertise; intermittent shedding causes misses.

Special stains and concentration methods matter.

## Where do antigen and PCR win?

Giardia and Crypto antigen/NAAT pathways are workhorses in many labs.

Multiplex PCR expands differential in persistent traveler or severe community diarrhea.

Molecular tests do not automatically quantify clinical severity.

  Key reference points
  MethodBest forLimitation

    O&P microscopyMany helminth eggsShedding; expertise
    Stool antigenGiardia/Crypto etc.Target-limited
    Multiplex PCRBroad diarrhea panelsInterpretation needed
    SerologyTissue/exposurePast vs active
    Tape testPinwormWrong for most stool pathogens

## When is serology the right door?

Toxoplasma in pregnancy/immunocompromise algorithms.

Strongyloides risk before steroids or transplant.

Some tissue helminths where stool is insensitive.

## How does stewardship look in practice?

IDSA: not all diarrhea needs stool testing.

Red flags—blood, fever, immunocompromise, persistence—raise testing value.

Reject empiric polypharmacy based on unvalidated kits.

Sources: [CDC DPDx](https://www.cdc.gov/dpdx/index.html); [IDSA 2017 infectious diarrhea](https://pmc.ncbi.nlm.nih.gov/articles/PMC5848254/); [CDC parasites causes](https://www.cdc.gov/parasites/causes/index.html).

Readers should dual-source primary literature, translate slogans into exposure units and effect sizes, and rank interventions by expected value under uncertainty. Cheap reversible steps often outrank extreme protocols. Opportunity cost is real: hours spent on unvalidated tests are hours not spent on sleep, training, protein adequacy, and primary care. Sex, life stage, comorbidities, medications, and geography change interpretation. Prefer falsifiable claims with named endpoints over multi-disease cure lists. Update beliefs when stronger trials appear rather than freezing identity around a single paper or influencer narrative. Measured curiosity beats both panic and complacency. Further reading should prioritize primary sources and consensus documents over secondary social summaries. When evidence is mixed, state both the signal and the limits in the same paragraph. When evidence is strong, still avoid overclaiming universality across populations. Pattern quality, dose, and adherence dominate most household decisions more than brand seals.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Household decisions should favor reversible experiments with measurable outcomes over identity diets or unvalidated testing cascades. When numbers conflict across agencies, report both the public-health target and the regulatory ceiling, then place personal labs on that ladder explicitly.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Household decisions should favor reversible experiments with measurable outcomes over identity diets or unvalidated testing cascades. When numbers conflict across agencies, report both the public-health target and the regulatory ceiling, then place personal labs on that ladder explicitly.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Household decisions should favor reversible experiments with measurable outcomes over identity diets or unvalidated testing cascades. When numbers conflict across agencies, report both the public-health target and the regulatory ceiling, then place personal labs on that ladder explicitly.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Household decisions should favor reversible experiments with measurable outcomes over identity diets or unvalidated testing cascades. When numbers conflict across agencies, report both the public-health target and the regulatory ceiling, then place personal labs on that ladder explicitly.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Household decisions should favor reversible experiments with measurable outcomes over identity diets or unvalidated testing cascades. When numbers conflict across agencies, report both the public-health target and the regulatory ceiling, then place personal labs on that ladder explicitly.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Household decisions should favor reversible experiments with measurable outcomes over identity diets or unvalidated testing cascades. When numbers conflict across agencies, report both the public-health target and the regulatory ceiling, then place personal labs on that ladder explicitly.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Household decisions should favor reversible experiments with measurable outcomes over identity diets or unvalidated testing cascades. When numbers conflict across agencies, report both the public-health target and the regulatory ceiling, then place personal labs on that ladder explicitly.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Household decisions should favor reversible experiments with measurable outcomes over identity diets or unvalidated testing cascades. When numbers conflict across agencies, report both the public-health target and the regulatory ceiling, then place personal labs on that ladder explicitly.

## Sources

1. [CDC DPDx](https://www.cdc.gov/dpdx/index.html)
2. [IDSA 2017 infectious diarrhea](https://pmc.ncbi.nlm.nih.gov/articles/PMC5848254/)
3. [CDC parasites causes](https://www.cdc.gov/parasites/causes/index.html)

---
Source: https://healthcanon.com/environmental-health/parasites-diagnostic-op-pcr-serology-map
Index: https://healthcanon.com/llms.txt · Full text: https://healthcanon.com/llms-full.txt